All three tenses have at least two readings, so the archetype blend applies as printed.
Of the nine metrics, 3 read as filed from the record and 6 are SI estimates, each with its reasoning, its confidence and what would change it on its card.
What did they actually do?
Has it survived what it has been through?
1 warning event since 2019; the latest 2019-12-20.
From the record
Immunovant, Inc.'s filings since 2019 show 1 warning event: an auditor change (8-K item 4.01, the latest 2019-12-20) (its current reports).
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What has it actually done, year after year?
SI estimate 4.9/10, confidence 20 of 100 (family median).
SI estimate Inferred, not read as filed
From the record
SI estimate, not a filed reading: Immunovant, Inc.'s track record is put at 4.9 of 10 with a confidence of 20 of 100, because fewer than three filed years of revenue on file, so the desk assumes the typical reading of its industry family, the median of 103 members with one. Its next annual report on file with the inputs replaces this estimate with the filed reading.
How has it treated the people who own it?
SI estimate 6.3/10, confidence 35 of 100 (one part).
SI estimate Inferred, not read as filed
From the record
SI estimate, not a filed reading: Immunovant, Inc.'s shareholder treatment is put at 6.3 of 10 with a confidence of 35 of 100, because read from one part only, the share count over the years, which ranks in the top 37% of 146 in its family; fewer than two of the parts can be read: the share count over the years, and the cash returned against a positive operating cash flow or net income. A filing that carries the missing parts replaces this estimate with the filed reading.
What are they doing right now?
Is it financially healthy right now?
ROE -59%: lost 59¢ per shareholder dollar. Leverage 11%: owes 11¢ per asset dollar.
From the record
Return on equity: in the fiscal year ended 2026-03-31, Immunovant, Inc. lost about 59 cents for every dollar of shareholders' money. Leverage: it owed about 11 cents per dollar of assets, and net share issuance: its share count grew 20.4% over the year (the filed statements).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
How strong is its position in its industry?
SI estimate 4.9/10, confidence 20 of 100 (family median).
SI estimate Inferred, not read as filed
From the record
SI estimate, not a filed reading: Immunovant, Inc.'s industry position is put at 4.9 of 10 with a confidence of 20 of 100, because no filed revenue on file, so the desk assumes the typical reading of its industry family, the median of 102 members with one. Its next annual report on file with the inputs replaces this estimate with the filed reading.
What are the people in charge doing?
bottom 38% of 110 in its family for leadership; chief executive since 2025.
From the record
Immunovant, Inc.'s leadership, from its insiders' filings and its current reports: the chief executive on the record is Venker, Eric (Chief Executive Officer, as filed), filing under that title since 2025-07-30, 1.3 years (bottom 16% of its family); the 12 officers and directors filing in the last fifteen months have been on the record a median of 3.2 years (bottom 16%); 3 officer or director changes were reported on Form 8-K since 2023-11-13, against the 12 people in charge now (top 19%; fewer changes for each person reads higher) (the Form 4 record, its Form 8-K reports). Years count from a person's first filing in the SEC's data sets, which begin in 2006, so each is a floor.
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What are they set up to do next?
How much room does it have to grow?
SI estimate 9.6/10, confidence 35 of 100 (one part).
SI estimate Inferred, not read as filed
From the record
SI estimate, not a filed reading: Immunovant, Inc.'s room to expand is put at 9.6 of 10 with a confidence of 35 of 100, because read from one part only, cash less debt against assets, which ranks in the top 4% of 152 in its family; the record does not carry two of the four parts: cash less debt against assets, cash from operations less capital spending against revenue, gross margin, research against revenue. A filing that carries the missing parts replaces this estimate with the filed reading.
What could actually drive growth from here?
SI estimate 4.9/10, confidence 20 of 100 (family median).
SI estimate Inferred, not read as filed
From the record
SI estimate, not a filed reading: Immunovant, Inc.'s growth drivers is put at 4.9 of 10 with a confidence of 20 of 100, because the record does not carry three filed years of revenue and two of the four parts: acceleration, the newest year's growth, the growth of research and of capital spending, so the desk assumes the typical reading of its industry family, the median of 101 members with one. Its next annual report on file with the inputs replaces this estimate with the filed reading.
Did its newest year beat what its own record pointed to?
SI estimate 5.1/10, confidence 20 of 100 (family median).
SI estimate Inferred, not read as filed
From the record
SI estimate, not a filed reading: Immunovant, Inc.'s expectations vs reality is put at 5.1 of 10 with a confidence of 20 of 100, because the record does not carry four filed years of revenue and two of the three parts: revenue against the prior pace, earnings against the prior average, the margin change, so the desk assumes the typical reading of its industry family, the median of 73 members with one. Its next annual report on file with the inputs replaces this estimate with the filed reading.
The grade is the company against its own industry, from its filings. It is not a view on the share price. How the grade is made